AI Colonoscopy Boosts ADR by 20%, IBS Food Test Breakthrough & CRC Screening at 45

Major breakthroughs reshape GI practice this week: AI-assisted colonoscopy proves it can boost adenoma detection rates by 20 percentage points while saving time, the first nutrition diagnostic meets FDA endpoints for IBS management, and new Kaiser data reinforces screening at age 45. Plus, updates on neonatal malabsorption therapy, GI practice consolidation, and the booming OR integration market.

🤖 AI Colonoscopy Reaches New Milestone

• World Journal of Gastroenterology publishes 47-page state-of-the-art review
• CADe platforms increase ADR by average of 20 percentage points
• Shortens withdrawal time by 45 seconds
• Authors call for cost-effectiveness studies and standardized training
• Read the full review

🍽️ Breakthrough IBS Food Test Meets FDA Endpoints

• Biomerica's inFoods® IBS test achieves primary endpoint in RCT
• 238 patients across 8 U.S. academic centers
• FDA pain-responder rate: 59.6% vs 42.2% (placebo diet)
• Strongest efficacy in IBS-M: 66% responders
• First nutrition diagnostic to meet prespecified IBS endpoints
• Published in Gastroenterology    

🏥 Practice Consolidation Update

• Dignity Health acquires Sierra Nevada Gastroenterology
• Grass Valley, CA clinic closes June 9, reopens June 16
• Includes endoscopy suite upgrades and EPIC integration
• Reflects ongoing health system consolidation trend

👶 First Neonatal Malabsorption Drug Trial Begins

• Elgan Pharma & Chiesi launch Phase 3 NEOMAL study
• ELGN-2112 for very-low-birth-weight neonates (n≈240)
• Primary endpoint: weight-for-age z-score at 6 weeks
• Could become first pharmacologic therapy for condition

📊 CRC Screening at 45 Validated

• Kaiser Northern California cohort study in JAMA
• 25,000 patients comparing ages 45-49 vs 50-54
• Similar rates of advanced adenoma, serrated lesions, CRC
• Only difference: adenoma prevalence (35.4% vs 40.8%)
• Reinforces USPSTF/ACS guidelines

💻 OR Integration Market Forecast

• Market projected to reach $6.9 billion by 2031
• 5% CAGR driven by 4K imaging, cloud routing, hybrid suites
• Hospitals bundling AI-ready colonoscopy platforms
• Capital planning implications for 2026

Key Takeaways

1. AI in colonoscopy is ready for prime time - but needs proper implementation
2. Personalized nutrition arrives for IBS - test-guided diets outperform placebo
3. Age 45 screening is evidence-based - update your protocols now
4. Consolidation continues - independent groups need strategic planning
5. Tech investment is mandatory - 4K and AI capabilities becoming standard

Resources & References

• AI Colonoscopy Review (World J Gastroenterol 2025)
• inFoods® IBS RCT (Gastroenterology June 2025)
• Kaiser CRC Screening Study (JAMA June 2025)
• iData OR Integration Market Report (June 2025)
• NEOMAL Trial Registration (ClinicalTrials.gov)

Episode Sponsor

DigestiveJobs.com - Find gastroenterology, hepatology and endoscopy careers worldwide. Post your GI job FREE this month! Visit DigestiveJobs.com

Disclaimer

This podcast provides educational content for healthcare professionals. Information should not replace clinical judgment. Consult primary sources and guidelines for patient care decisions.

https://www.gastroendopod.com